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RESUMO – Introdução: Os doentes com antecedentes pessoais de cancro cutâneo não melanoma têm um risco aumentado 
de desenvolver outro cancro cutâneo e alguns estudos sugerem que o tipo histológico do primeiro tumor pode ser preditor 
dos subsequentemente diagnosticados. O objetivo deste estudo foi avaliar a correlação entre o tipo histológico do primeiro 
cancro cutâneo não-melanoma e os subsequentemente diagnosticados no mesmo hospedeiro, em indivíduos imunocompe-
tentes e com diferentes causas de imunodepressão. Métodos: Estudo retrospetivo em que foram incluídos todos os doentes 
sem antecedentes de cancro cutâneo, com o diagnóstico de dois ou mais cancros cutâneos não-melanoma entre 1 de Janeiro 
de 2008 e 31 de Dezembro de 2017. Resultados: Incluídos um total de 413 doentes, 51 (12,4%) dos quais imunodeprimi-
dos. Verificou-se uma associação significativa entre o tipo histológico do primeiro e dos cancros cutâneos não-melanoma 
subsequentemente diagnosticados, quer em doentes imunocompetentes, quer em imunodeprimidos, com uma maior proba-
bilidade de desenvolver um tumor do mesmo tipo histológico (p<0,001). Esta associação foi também significativa em doentes 
com uma neoplasia hematológica. O intervalo médio entre os dois diagnósticos foi de 30 meses (intervalo 7-111). Quarenta 
e três doentes (10,4%) apresentaram um tumor subsequente após mais de cinco anos de seguimento. Conclusões: O tipo 
histológico do primeiro cancro cutâneo não-melanoma foi preditor do risco de desenvolver um tumor do mesmo tipo. Pela 
primeira vez, esta correlação foi identificada em doentes com uma neoplasia hematológica. Os doentes de alto risco devem 
ter um seguimento prolongado de pelo menos dez anos.  
PALAVRAS-CHAVE – Carcinoma Basocelular; Carcinoma de Células Escamosas; Imunossupressão; Neoplasias da Pele.
Predictive Value of the First Non-Melanoma Skin 
Cancer: A Retrospective Study   
ABSTRACT – Introduction: Patients with previous non-melanoma skin cancer have an increased risk of developing another 
skin cancer and some studies suggest that the histological type of the incident tumour can predict the one of the subsequently 
diagnosed. The aim of this study was to assess a correlation between the histological type of the first and the subsequent non-
-melanoma skin cancer diagnosed in immunocompetent patients and in different settings of immunosuppression. Methods: A 
retrospective study was conducted on all patients without previous skin cancer, with the diagnosis of two or more non-melanoma 
skin cancer between January 1st, 2008 and December 31th, 2017. Results: A total of 413 patients were included. Fifty-one indi-
viduals (12.4%) were immunosuppressed. There was a significative association between the histological type of the first and the 
subsequent non-melanoma skin cancer diagnosed both in immunocompetent and in immunosuppressed patients, with a higher 
probability of developing a tumour of the same histological type (p<0.001). This association was also significative in patients 
with the diagnosis of a hematologic malignancy. The mean interval between the two diagnoses was 30 months (range 7-111). 
Forty-three patients (10.4%) presented a subsequent tumour after more than five years of follow-up. Conclusion: The histological 
type of the incident non-melanoma skin cancer predicted the risk of developing another tumour of the same type. For the first 
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INTRODUCTION
Non-melanoma skin cancer (NMSC) is the most com-
mon malignancy in fair-skinned people and its incidence is 
increasing worldwide.1-3
Patients with previous NMSC are at increased risk of 
developing another skin cancer and some studies suggest 
that the histological type of the incident tumour can predict 
the one of the subsequently diagnosed.4,5 This association 
was reported not only in the general population, but also 
in solid organ transplant recipients (SOTR).4-7
However, the predictive value of the histological type 
of the NMSC diagnosed in immunosuppressed patients is 
seldom studied. Furthermore, the timing and risk factors 
for subsequent skin malignancies in these patients are also 
poorly characterized. 
The aim of this study was to assess a possible correla-
tion between the histological type of the first NMSC and 
of those subsequently diagnosed in immunocompetent 
patients and in different settings of immunosuppression, 
namely in SOTR, in human immunodeficiency virus (HIV) 
infection, in patients with the a hematologic malignancy 
and/or under immunosuppressive therapy. 
MATERIAL & METHODS 
A retrospective study was conducted on all patients without 
previous skin cancer, with the diagnosis of two or more non-
-synchronous NMSC between January 1st, 2008 and Decem-
ber 31th, 2017, at Hospital de Santa Maria, a tertiary teaching 
hospital in Lisbon, Portugal. All cases had histological confir-
mation. Data was obtained by reviewing dermatopathology 
registries and the clinical records of dermatology visits. We 
considered synchronous malignancies the ones that presented 
within the first six months following the diagnosis of the first 
NMSC. We excluded tumours situated on the genital area and 
those contiguous to a scar or at the site of a previous surgical 
procedure, which could represent a recurrence of a previous 
skin cancer. The information recorded for each patient inclu-
ded gender, age, causes of immunosuppression, the interval 
for the second diagnosis, number of tumours, anatomic loca-
tion and histologic type of skin cancers. 
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time, we showed this correlation in patients with a hematologic malignancy. High-risk individuals may benefit from a long-lasting 
follow-up of at least ten years.
KEYWORDS – Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Immunosuppression; Skin Neoplasms.
Figure 1 - Flowchart of study exclusions; Legend: HIV: Human immunodeficiency virus; NMSC: Non-melanoma skin cancer; SOTR: Solid organ 
transplant recipients. 
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Data was analysed using IBM SPSS Statistics® (Statistical 
Package for the Social Sciences, version 24, SPSS Inc, Chi-
cago, IL, USA). Categorical variables were presented as 
frequencies and percentages and were compared with use 
of chi-square test or Fisher’s exact test, when there were 
expected frequencies <5. Continuous variables were pre-
sented as means and standard deviations or medians and 
interquartile ranges, for variables with skewed distribution. 
These variables were compared with the use of Student’s 
t-test. All reported P values are two-tailed, with a P value of 
0.05 indicating statistical significance.
The study was conducted in accordance with the De-
claration of Helsinki and was approved by the local ethics 
review board (Comissão de Ética do Hospital de Santa 
Maria, Centro Hospitalar Universitário Lisboa Norte).
RESULTS
The sample included 577 patients who were diag-
nosed with two NMSC, but due to exclusion criteria 
(n=123) or insufficient data (n=21), 144 cases were ex-
cluded (Fig.1). A total of 413 patients without previous 
skin cancer developed two non-synchronous NMSC and 
were included. All patients were Caucasian. Patient de-
mographical and clinical characteristics are shown in 
Table 1. 
Fifty-one (12.4%) individuals were immunosuppres-
sed (Table 2). Fifteen patients shared more than one 
cause of immunosuppression. The ten SOTR had immu-
nosuppressive regimens composed of three drugs and 
five patients with the diagnosis of a haematologic ma-
lignancy also took immunosuppressive drugs. 
Patients presented a total of 1000 NMSC, 508 inci-
dent and 492 metachronous tumours. Sixty-five patients 
(15.7%) had synchronous tumours at presentation. Pre-
-neoplastic dermatoses, in particular actinic keratosis, 
were found more frequently in patients who presented 
a squamous cell carcinoma (SCC) than in those with a 
basal cell carcinoma (BCC) (84.4% vs 52.0%; p<0.001). 
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Table 1 - Patient demographical and clinical characteristics.
All patients 
(n=413)
Immunocompetent 
(n=362; 87.6%)
Immunosuppressed 
(n=51; 12.4%)
Age at first NMSC, mean (SD), y 73.6 (10.3) 74.1 (10.1) 70.2 (11.9)
Male gender, No. (%) 261 (63.2) 232 (64.1) 29 (56.9)
Incident 
NMSC
Number of tumours, 
No. (%)
Single 348 (84.3) 305 (84.3) 43 (84.3)
Multiple 65 (15.7) 57 (15.8) 8 (15.7)
Histologic type, No. 
(%)
BCC 323 (78.2) 289 (79.8) 34 (66.7)
SCC 80 (19.4) 65 (18.0) 15 (29.4)
Both 10 (2.4) 8 (2.2) 2 (3.9)
Photoexposed area, 
No. (%)
Yes 295 (71.4) 254 (70.2) 41 (80.4)
No 100 (24.2) 91 (25.1) 9 (17.7)
Both 18 (4.4) 17 (4.7) 1 (2.0)
Subsequent 
NMSC
Number of tumours, 
No. (%)
Single 351 (85.0) 307 (84.8) 44 (86.3)
Multiple 62 (15.0) 55 (15.2) 7 (13.7)
Histologic type, No. 
(%)
BCC 314 (76.03) 282 (77.9) 32 (62.8)
SCC 84 (20,3) 68 (18.8) 16 (31.4)
Both 15 (4.8) 12 (3.3) 3 (5.9)
Photoexposed area, 
No. (%)
Yes 278 (67.3) 242 (66.9) 36 (70.6)
No 119 (28.8) 106 (29.3) 13 (25.59)
16 (3.9) 14 (3.9) 2 (3.9)
Time between incident and subsequent NMSC, mean (SD), m 30.4 (21.4) 30.3 (21.2) 31.1 (22.7)
BCC; Basal cell carcinoma; NMSC: Non-melanoma skin cancer; SCC: Squamous cell carcinoma
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The anatomic distribution of the NMSC diagnosed is 
shown in Table 3. The most common body surface loca-
tion was the head and/or neck. A total of 353 incident 
NMSC presented in this photoexposed area occurred in 
303 patients (73.4%). Patients with incident NMSC in this 
anatomic location were in average older than the remain-
der (M=74.86 vs 70.30; p<0.001). Moreover, these pa-
tients were significantly more likely to present synchronous 
tumours (p=0.003) and a SCC as the first skin cancer 
diagnosed (p=0.032). Patients who presented an incident 
NMSC in the head and/or neck had a higher probability 
of developing a subsequent malignancy in the same body 
area (p<0.001). 
The histological type of the incident NMSC was signi-
ficantly associated with the same histological type in the 
subsequent cutaneous malignancies diagnosed, both in 
immunocompetent and in immunosuppressed patients, 
both with BCC and SCC as the incident tumour (p<0.001). 
This association was also significant in patients with the 
diagnosis of a haematologic malignancy, either those 
presenting with BCC (p=0.004) or SCC (p=0.032) as the 
first diagnosed NMSC.
The mean time between the diagnosis of the incident 
and the metachronous NMSC was 30 months (+/- 21.4). 
The interval between the two diagnoses ranged between 7 
and 111 months. Forty-three patients (10.4%) developed a 
second tumour after a follow-up time longer than 60 mon-
ths. The mean number of months was significantly lower 
in patients that presented a SCC than in those who pre-
sented a BCC as the incident NMSC (M=25.68 vs 31.49; 
p=0.018).
DISCUSSION
In this study, there was a significative association be-
tween the histological type of the incident NMSC and the 
subsequently diagnosed tumours, both in immunocompe-
tent and in immunosuppressed patients. This correlation 
was previously reported in two meta-analysis and in a re-
cently published retrospective study.4-6 Although the histo-
logical type of the first NMSC diagnosed after solid organ 
transplant was identified as a strong predictor for the deve-
lopment of a subsequent skin cancer of the same type, this 
association is scarcely studied in other groups of immuno-
suppressed patients.7-8 As far as we were able to search in 
the literature, this is the first study that identifies a correla-
tion between the histological type of the first NMSC and of 
the subsequently diagnosed in individuals with a hemato-
logic malignancy. 
Skin carcinogenesis is a complex and multifactorial 
process, in which genetic factors interact with lifestyle ha-
bits.5 Differences in sun exposure may contribute to the ten-
dency of developing NMSC of the same histological type. 
Simultaneously, it is possible that patients develop a state 
of immunologic tolerance after the first NMSC, raising the 
risk of subsequent tumours of the same histological type.8 
As with previous studies, the head and/or neck region 
was the most frequent anatomic location of NMSC.6,9 Pa-
tients with an incident malignancy in this site were older, 
with multiple tumours at presentation and had higher pro-
bability of presenting a SCC. Moreover, these individuals 
had a higher risk of developing a subsequent tumour in 
the same body site. Altogether, these associations may put 
in evidence the mechanism of field cancerization, highli-
ghting the critical role of chronic and cumulative sun expo-
sure as the most important risk factor for the development 
of NMSC in this anatomic area.10 
The correlation between follow-up times after the diag-
nosis of a NMSC and outcomes is scarcely studied and 
the duration of surveillance remains controversial.5 Cur-
rent guidelines recommend surveillance over a period of at 
least three to five years after the diagnosis and treatment 
of an incident NMSC, based on studies that reported a re-
markable reduction of the risk of developing a subsequent 
tumour after this time.4,5 However, a cohort study that pros-
pectively followed up a large number of patients for more 
than ten years found a five-year probability of developing 
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Table 2 - Immunosuppression causes.
Immunosuppressive therapy, No. (%) 30 (7.3)
Number of drugs, No. (%)
One
Two
Three
15 (3.6)
5 (1.2)
10 (2.4)
Drug, No. (%)
Corticosteroid
MMF
Cyclosporine
Azathioprine
Methotrexate 
Tacrolimus
Sirolimus
24 (5.8)
9 (2.2)
6 (1.5)
5 (1.2)
4 (1.0)
3 (0.7)
1 (0.2)
Hematologic malignancy, No. (%) 24 (5.8)
Diagnosis, No. (%)
Myeloproliferative syndrome
Non-Hodgkin lymphoma 
Other leukaemia
Acute myeloid leukaemia / myelodysplastic syndrome
Multiple myeloma
Other
9 (2.2)
7 (1.7)
3 (0.7)
2 (0.5)
2 (0.5)
1 (0.2)
Solid organ transplant, No. (%) 10 (2.4)
Organ, No. (%)
Kidney
Heart
9 (2.2)
1 (0.2)
HIV infection, No. (%) 2 (0.5)
HAART, No. (%) 2 (0.5)
HAART: highly active antiretroviral therapy; HIV: Human immunodefi-
ciency virus; MMF: Mycophenolate mofetil
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a subsequent NMSC of 40.7%, value that increased to 
59.6% at ten years.11 In the present study, 10.4% of the pa-
tients only presented a subsequent NMSC after more than 
five years of follow-up. The significative risk of presenting 
a skin cancer after the currently recommended surveillance 
period might justify extending the follow-up of these pa-
tients for at least ten years after the diagnosis of a NMSC. 
The main limitations of this study arise from the fact that 
this is a retrospective study. One of the main weaknesses is 
the small number of immunosuppressed patients included, 
that limited confident comparisons in some subgroups, na-
mely those with HIV infection and SOTR. Moreover, the he-
terogeneity of drugs prescribed and the different degrees 
of immunosuppression, did not allowed us to rigorously 
assess patients taking immunosuppressive drugs. Data on 
specific skin type, sun exposure habits and the adoption of 
sun-protective measures after the incident NMSC were not 
available, but all the patients were Caucasian, the majority 
with a skin Fitzpatrick phototype II or III. 
CONCLUSION
In the present study, the histological type of the incident 
NMSC predicted the risk of developing another tumour of 
the same type, confirming data from previous studies in the 
general population and in immunosuppressed patients. To 
the best of our knowledge, for the first time, we showed this 
correlation in individuals with a haematologic malignancy. 
This finding may contribute to improve risk stratification 
and surveillance after the diagnosis of a NMSC, particular-
ly in immunosuppressed patients with SCC. 
Current guidelines recommend lifelong intensive der-
matologic surveillance to all SOTR with a history of NMSC. 
Also other therapeutically immunosuppressed and other 
high risk individuals, namely those with haematological 
malignancies, may benefit from a long-lasting follow-up 
of at least ten years, with shorter intervals between each 
evaluation in the first years.
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Table 3 - Body surface distribution of diagnosed tumours. 
First NMSC Subsequent NMSC
Histologic type BCC SCC BCC SCC
Bo
dy
 s
ite
, 
N
o.
Head and/or neck 271 82 256 85
Face 194 52 188 60
Ears 19 8 13 6
Scalp 43 20 42 19
Neck 15 2 13 0
Chest and/or abdomen 49 1 27 3
Back and/or buttocks 51 2 49 1
Upper limbs 12 2 25 6
Hands 0 10 0 8
Lower limbs 25 3 21 8
Feet 0 0 1 2
Total 408 100 379 113
BCC: Basal cell carcinoma; NMSC: Non-melanoma skin cancer; SCC: Squamous cell carcinoma
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